X0206 3 2015-04-15 0 0001434647 KEMPHARM, INC KMPH 0001638364 Plooster Matthew R C/O KEMPHARM, INC. 2656 CROSSPARK ROAD, SUITE 100 CORALVILLE IA 52241 1 0 0 0 Series C Convertible Preferred Stock Common Stock 25642 D Series C Convertible Preferred Stock Common Stock 8381 I By TD Ameritrade Clearing Inc. Custodian FBO Matthew Ryan Plooster Roth IRA, as trustee Series D Convertible Preferred Stock Common Stock 8456 D Warrant to Purchase Common Stock (right to buy) 3.90 2016-03-23 Common Stock 3572 D Warrant to Purchase Series D Preferred Stock (right to buy) 0.78 Common Stock 384 D Series A Convertible Preferred Stock Common Stock 1701011 I By Bridgepoint Investment Partners I LLLP Series B Convertible Preferred Stock Common Stock 1511279 I By Bridgepoint Investment Partners I LLLP Immediately convertible into shares of the Issuer's Common Stock at the Reporting Person's election. The shares will automatically convert into 3,418 shares of the Issuer's Common Stock immediately upon the closing of a Qualified Public Offering (as defined in the Issuer's Restated Certificate of Incorporation). The shares will automatically convert into 1,117 shares of the Issuer's Common Stock immediately upon the closing of a Qualified Public Offering. The shares will automatically convert into 1,127 shares of the Issuer's Common Stock immediately upon the closing of a Qualified Public Offering. The shares do not have an expiration date. Immediately exercisable. The warrant will automatically convert into a warrant to purchase 51 shares of the Issuer's Common Stock at an exercise price of $5.85 per share immediately upon the closing of a Qualified Public Offering. The warrant expires as of 5:00 p.m. C.S.T. on the earliest of (i) June 2, 2019 and (ii) the effective date of the closing of a Company Sale Transaction (as such term is defined in the warrant). The shares will automatically convert into 226,801 shares of the Issuer's Common Stock immediately upon the closing of a Qualified Public Offering. The shares directly held by Bridgepoint Investment Partners I LLLP, or Bridgepoint, are indirectly held by its general partner, Bridgepoint Capital Partners, LLP, or BPCP. The individual managers of BPCP are Matthew R. Plooster and Adam S. Claypool. Matthew R. Plooster and Adam S. Claypool share voting and dispositive power with regard to the shares directly held by Bridgepoint. The shares will automatically convert into 201,503 shares of the Issuer's Common Stock immediately upon the closing of a Qualified Public Offering. /s/ James C.T. Linfield, Attorney-in-Fact 2015-04-15